
BIORA THERAPEUTICS INC (PROG) Fundamental Analysis & Valuation
NASDAQ:PROG • US74319F1075
Current stock price
0.8845
-0.03 (-3.47%)
At close:
0.9
+0.02 (+1.75%)
After Hours:
This PROG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. PROG Profitability Analysis
1.1 Basic Checks
- In the past year PROG has reported negative net income.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -227.32% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -517.86% | ||
| PM (TTM) | -966.06% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. PROG Health Analysis
2.1 Basic Checks
- The number of shares outstanding for PROG has been increased compared to 1 year ago.
- The debt/assets ratio for PROG is higher compared to a year ago.
2.2 Solvency
- PROG has an Altman-Z score of -12.84. This is a bad value and indicates that PROG is not financially healthy and even has some risk of bankruptcy.
- PROG has a Debt/Equity ratio of -1.49. This is a healthy value indicating a solid balance between debt and equity.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | -1.49 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.84 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 1.60 indicates that PROG should not have too much problems paying its short term obligations.
- PROG has a Quick Ratio of 1.60. This is a normal value and indicates that PROG is financially healthy and should not expect problems in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.6 |
3. PROG Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 68.83% over the past year.
- The Revenue for PROG has decreased by -65.54% in the past year. This is quite bad
- The Revenue for PROG have been decreasing by -78.64% on average. This is quite bad
EPS 1Y (TTM)68.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.4%
Revenue 1Y (TTM)-65.54%
Revenue growth 3Y-78.64%
Revenue growth 5YN/A
Sales Q2Q%-96.95%
3.2 Future
- PROG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.23% yearly.
- Based on estimates for the next years, PROG will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y77.59%
EPS Next 2Y33.26%
EPS Next 3Y20.89%
EPS Next 5Y12.23%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. PROG Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for PROG. In the last year negative earnings were reported.
- Also next year PROG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -1.53 |
4.3 Compensation for Growth
- PROG's earnings are expected to grow with 20.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.26%
EPS Next 3Y20.89%
5. PROG Dividend Analysis
5.1 Amount
- PROG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROG Fundamentals: All Metrics, Ratios and Statistics
0.8845
-0.03 (-3.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)05-10 2022-05-10/amc
Earnings (Next)08-10 2022-08-10
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners8.45%
Ins Owner Change0%
Market Cap162.92M
Revenue(TTM)25.61M
Net Income(TTM)-247.41M
Analysts82.86
Price Target4.08 (361.28%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.36 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | -1.53 |
EPS(TTM)-2.23
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.14
BVpS-0.46
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -227.32% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | -517.86% | ||
| PM (TTM) | -966.06% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | -1.49 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.6 | ||
| Altman-Z | -12.84 |
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.4%
EPS Next Y77.59%
EPS Next 2Y33.26%
EPS Next 3Y20.89%
EPS Next 5Y12.23%
Revenue 1Y (TTM)-65.54%
Revenue growth 3Y-78.64%
Revenue growth 5YN/A
Sales Q2Q%-96.95%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
BIORA THERAPEUTICS INC / PROG Fundamental Analysis FAQ
What is the ChartMill fundamental rating of BIORA THERAPEUTICS INC (PROG) stock?
ChartMill assigns a fundamental rating of 2 / 10 to PROG.
What is the valuation status of BIORA THERAPEUTICS INC (PROG) stock?
ChartMill assigns a valuation rating of 0 / 10 to BIORA THERAPEUTICS INC (PROG). This can be considered as Overvalued.
Can you provide the profitability details for BIORA THERAPEUTICS INC?
BIORA THERAPEUTICS INC (PROG) has a profitability rating of 0 / 10.
What is the earnings growth outlook for BIORA THERAPEUTICS INC?
The Earnings per Share (EPS) of BIORA THERAPEUTICS INC (PROG) is expected to grow by 77.59% in the next year.